The effect of disclosure on adherence to antiretroviral therapy among adults living with HIV in Ethiopia: a systematic review and meta-analysis

Table 1 Characteristics of included studies for meta-analysis, 2010–2015, Ethiopia

Study #	Author	Publication year	Region	Sample size	Good Adherence Definition	Disclosure Outcomes	Good adherence		OR
Study #	Author	Publication year	Region	Sample size	Good Adherence Definition	Disclosure Outcomes	Among disclose	Among non-disclose
1	Mitiku et al. [37]	2013	Harari	239	> 95% of prescribed ARV drugs for the past 7 days.	Family or others	164/208	44/208	1.09
2	Mohammed et al. [38]	2015	Oromia	237	< 3 missed doses/day over study period	Community	175/197	22/197	3.41
3	Ketema et al. [36]	2015	Amhara	422	0 missed dose during the 30-day period prior to filling out the self-report.	Religious leaders and others	357/422	65/422	1.96
4	Alagaw et al. [33]	2013	SNNPR	357	> = 95% of prescribed drugs in past 7 days.	No specifics regarding disclosure	281/312	31/312	2.59
5	Tsega et al. [18]	2015	Amhara	351	< 3 missed doses over the entire time of therapy (Range: >6mo to < 3 yr)	Family	265/284	19/284	1.13
6	Gelan [35]	2010	SNNPR	277	Patients who reported an intake of 95% or more of the prescribed medication	Partner, family, relatives, friends and community	86/182	96/182	1.85
7	Asmare et al. [34]	2014	Amhara	377	< 3 missed doses per month	Family/Relatives	37/55	18/55	0.85

ISSN: 1471-2334